Business Wire | Jan 3, 2022 07:30AM EST

Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Jan. 03, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 03, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD, will present at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually on Wednesday, January 12, 2022, at 2:15pm ET.

A live webcast of the presentation will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir's wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005085/en/

CONTACT: INVESTOR: Lisa Hayes Vice President, Investor Relations and Corporate Communications 908-868-8926 Lisa.Hayes@cyteir.com

CONTACT: MEDIA: Michele Parisi 925-429-1850 mparisi@forwardhealthinc.com